undamentalytics Newsletter
Sign in

Beta Bionics, Inc. balance sheet

At the end of fiscal 2025, Beta Bionics, Inc. had total assets of $329m, total liabilities of $41.1m and shareholders' equity of $288m. It held $31.6m in cash against $0 of debt: net cash of $31.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents27303282
Receivables4121721
Inventory1132223
Total current assets104133268293
Total assets110150329444
Accounts payable1355
Deferred revenue (current)0122
Total current liabilities11213133
Total debt0000
Total liabilities51744142
Shareholders' equity−203−245288401
Non-controlling interests and other (assets − liabilities − equity)262321——
Net debt (negative = net cash)−27−30−32−82
Shares outstanding—7m44m54m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BBNX vs RXSTANIK vs BBNXBBNX vs OMBBNX vs INFU

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Beta Bionics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Beta Bionics, Inc.